2,197
Views
14
CrossRef citations to date
0
Altmetric
Original Article

5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells

, , , , &
Pages 2054-2065 | Received 10 Aug 2017, Accepted 18 Nov 2017, Published online: 05 Dec 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Zohreh Mirveis, Maryam Kouchak, Masoud Mahdavinia & Nadereh Rahbar. (2022) Novel and efficient method for loading aptamer-conjugated liposomes with arsenic trioxide for targeting cancer cells. Journal of Liposome Research 32:3, pages 276-283.
Read now
Hanieh Abbasi, Nadereh Rahbar, Maryam Kouchak, Parna Khalil Dezfuli & Somayeh Handali. (2022) Functionalized liposomes as drug nanocarriers for active targeted cancer therapy: a systematic review. Journal of Liposome Research 32:2, pages 195-210.
Read now
Zahra Shakib, Asma Mahmoudi, Seyedeh Alia Moosavian & Bizhan Malaekeh-Nikouei. (2022) PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor. Drug Development and Industrial Pharmacy 48:2, pages 69-78.
Read now
Mohammad Mashreghi, Mahdi Faal Maleki, Maryam Karimi, Fatemeh Kalalinia, Ali Badiee & Mahmoud Reza Jaafari. (2021) Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. Journal of Drug Targeting 29:6, pages 617-630.
Read now
Baozhang Guan & Xingwang Zhang. (2020) Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications. International Journal of Nanomedicine 15, pages 1059-1071.
Read now

Articles from other publishers (9)

Mengwen Song, Ruiyuan Cao, Xingjuan Chen, Cui Wang, Xiaowen Xing, Wei Li, Yuexiang Li, Yajin Liao, Wu Zhong, Qihong Li & Zhiqiang Liu. (2023) Amplified Targeted Drug Delivery Independent of Target Number through Alternative Administration of Two Matched Nanoparticles. ACS Nano.
Crossref
Xiujuan Yin, Huimin Zhao, Zhenqiang He & Xiao Wang. (2023) Application of aptamer-functionalized nanomaterials in molecular imaging of tumors. Nanotechnology Reviews 12:1.
Crossref
Xiujuan Yin, Zhenqiang He, Weiying Ge & Zhenhua Zhao. (2023) Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors. Frontiers in Bioengineering and Biotechnology 11.
Crossref
Priyank Shah & Pravin Shende. (2022) Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy. Current Cancer Drug Targets 22:1, pages 31-48.
Crossref
Huma Khan, Vaidehi Makwana, Sofia Nascimento dos Santos, Carlos Eduardo Bonacossa de Almeida, Ralph Santos-Oliveira & Sotiris Missailidis. (2021) Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy. Pharmaceutics 13:8, pages 1239.
Crossref
Gyeongyun Go, Chang-Seuk Lee, Yeo Min Yoon, Ji Ho Lim, Tae Hyun Kim & Sang Hun Lee. (2021) PrPC Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells. International Journal of Molecular Sciences 22:4, pages 1976.
Crossref
Zhaoying Fu & Jim Xiang. (2020) Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. International Journal of Molecular Sciences 21:23, pages 9123.
Crossref
Gayathri Ravichandran & Aravind Kumar Rengan. (2020) Aptamer-Mediated Nanotheranostics for Cancer Treatment: A Review. ACS Applied Nano Materials 3:10, pages 9542-9559.
Crossref
Jie Li, Tiantian Tan, Liping Zhao, Mengmeng Liu, Yu You, Yiying Zeng, Dajing Chen, Tian Xie, Lele Zhang, Chaomei Fu & Zhaowu Zeng. (2020) Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review. ACS Applied Bio Materials 3:9, pages 5500-5528.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.